Lendacin (Ceftriaxone)

Ceftriaxone is a broad‑spectrum antibiotic used to treat infections caused by susceptible bacteria across several organ systems.

• Community‑acquired pneumonia: eradicates the causative pathogens and improves respiratory function.
• Bacterial meningitis: penetrates the cerebrospinal fluid to achieve bactericidal activity.
• Gonorrhea: eliminates Neisseria gonorrhoeae and prevents complications.
• Urinary tract infections: clears infection in the urinary tract and kidneys.
• Skin and soft‑tissue infections: resolves cellulitis and wound infections.
• Intra‑abdominal infections: treats peritonitis and intra‑abdominal abscesses.

• Ceftriaxone binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis, resulting in a bactericidal effect against a wide range of Gram‑positive and Gram‑negative organisms.

Adverse reactions may occur with ceftriaxone therapy and are categorized by frequency and severity.

Common Side Effects

• Injection site pain: mild discomfort at the intramuscular or intravenous site.
• Diarrhea: loose stools that may be self‑limiting.
• Rash: mild skin erythema or pruritus.
• Nausea: transient feeling of queasiness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Stevens‑Johnson syndrome: severe mucocutaneous reaction.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Hemolytic anemia: destruction of red blood cells.

Ceftriaxone should be used with clinical judgment and monitoring for safety.

• Assess renal function: adjust therapy in patients with impaired kidney function.
• Monitor liver enzymes: watch for hepatic adverse effects during prolonged use.
• Use caution in neonates: risk of bilirubin displacement and kernicterus.
• Review allergy history: avoid in patients with known severe beta‑lactam hypersensitivity.
• Adjust dose in hepatic impairment: consider reduced dosing if liver disease is present.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ceftriaxone may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Calcium‑containing solutions: risk of precipitation when mixed intravenously.
• Prolonged biliary therapy: may increase risk of biliary sludging.

Moderate Interactions (Monitor Closely)

• Warfarin: enhanced anticoagulant effect, monitor INR.
• Aminoglycosides: additive nephrotoxicity, monitor renal function.
• Oral contraceptives: possible reduction in contraceptive effectiveness.
• Probenecid: increased ceftriaxone plasma concentrations, adjust dose if needed.
• Diuretics: monitor electrolyte balance during combined therapy.